**Subject:** Economy The **2005 Amendment to Section 3(d) of Indian Patent Law** marked a significant milestone in India's pharmaceutical patent regime, balancing innovation protection with public health accessibility. ## Historical Context and Amendment
- The **TRIPS compliance deadline of 2005** necessitated India to introduce product patents in pharmaceuticals, leading to the amendment of Section 3(d).
- The amendment aimed to prevent **"evergreening"** - a practice where pharmaceutical companies extend patent protection through minor modifications without significant therapeutic benefits.
- Section 3(d) mandates that new forms of known substances must demonstrate **enhanced efficacy** to qualify for patent protection. ## Supreme Court's Interpretation in Novartis Case
- In the landmark **2013 Novartis vs Union of India** case, the Supreme Court rejected the patent application for **Glivec (imatinib mesylate)**.
- The court established that: - Mere **discovery of new forms** of known substances without improved efficacy is not patentable. - **Bioavailability enhancement** alone doesn't constitute improved efficacy. - The new form must demonstrate significant improvement in **therapeutic efficacy**. ## Advantages of the Decision
- **Access to Affordable Healthcare**: Enabled production of generic versions at significantly lower prices (**Rs. 8,000** vs **Rs. 1,20,000** per month).
- **Prevention of Evergreening**: Set a precedent against frivolous patent extensions.
- **Strengthened Generic Industry**: Boosted India's position as the **"pharmacy of the developing world"**.
- Promoted genuine **pharmaceutical innovation** focused on therapeutic improvements. ## Challenges and Concerns
- **International Criticism**: Faced opposition from multinational pharmaceutical companies.
- **Investment Concerns**: Potential deterrent to R&D investments in India.
- **Trade Relations**: Strained relationships with developed nations viewing it as weak IP protection.
- **Innovation Impact**: Possible discouragement of incremental innovation in drug development. The Supreme Court's interpretation of Section 3(d) exemplifies India's balanced approach to patent law, prioritizing **public health accessibility** while encouraging meaningful innovation. The decision continues to influence global pharmaceutical patent policies, positioning India as a leader in **equitable healthcare access** through robust generic medicine production.